AzTrials
AzTrials

HypoparathyroidismMR-hypoPTNCT04569604

QoL and Cognitive Function in Patients With Hypoparathyroidism

An observational study of Hypoparathyroidism and Pseudo Hypoparathyroidism, run by University of Aarhus at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Hypoparathyroidism (HypoPT) is a disease with inadequate production of parathyroid hormone (PTH) from the parathyroid glands leading to hypocalcemia. The most common form is postsurgical HypoPT due to neck surgery resulting in removed or damaged parathyroid glands. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Hypoparathyroidism, Pseudo Hypoparathyroidism
What is being tested?
MRI scans, Neuro cognitive tests and Questionnaires on Quality of Life
How many people
64 participants
Where
1 siteDenmark
Study dates
1 Oct 2019to 1 Dec 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The patients with postsurgical, non-surgical and pseudo hypoparathyroidism will be invited from our outpatient clinic to participate in the study. The healthy controls will be randomly recruited from the background population by an extract from the CPR register and an invitation to participate in the study will be send by electronic letter.

Who may be able to join

  • Patients:
  • Male or female with age between 18 and 70 years.
  • A low endogenous PTH production as verified by low plasma levels of intact PTH, necessitating treatment with 1-αhydroxylated vitamin D analogs.
  • HypoPT for 3 years with continuous alphacalcidol or calcitriol treatment prior to study entry (except for the patients with PHP).
  • Stable P-calcium levels 1 month prior to inclusion.
  • In case of thyroid disease, TSH within reference range within the last year
Show all 11Show fewer
  • Speaks and reads Danish
  • Controls:
  • Male or female with age between 18 and 80 years.
  • No known diseases in the calcium homeostasis
  • Speaks and reads Danish

Who cannot join

  • Reduced kidney function (eGFR < 30 mL/min/1.73m2).
  • Diabetes type 1 or 2
  • History of hypertension for more than two years (treated or untreated)
  • Clinical suspicion of major depression (also if treated)
  • Clinical suspicion of alcohol-related dementia
  • Other organic or psychiatric cause the patients symptoms
Show all 10Show fewer
  • Contraindications to contrast-enhanced MRI.
  • Metal implants close to the head, which will interfere with the MRI or pacemaker. The patients will complete a metal scheme.
  • Claustrophobia
  • Unwillingness to participate

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Clinic for Osteoporosis, Aarhus University Hospital

    Aarhus N, Jutland, 8200

Other trials in Denmark

About this study

Official title: Impaired Quality of Life and Cognitive Function in Patients With Hypoparathyroidism Might be Explained by Disturbed Capillary Flow Patterns in the Brain

Hypoparathyroidism (HypoPT) is a disease with inadequate production of parathyroid hormone (PTH) from the parathyroid glands leading to hypocalcemia. The most common form is postsurgical HypoPT due to neck surgery resulting in removed or damaged parathyroid glands.

HypoPT is a complex disease with a reduced Quality of life, mild cognitive impairment and in some patients have brain calcifications.

Read more

The aim of the present study is to investigate the cognitive function in patients with postsurgical and non-surgical (HypoPT) by neuropsychological assessments and magnetic resonance imaging (MRI).

The investigators will apply a contrast-enhanced MRI based method to HypoPT patients and age- and gender matched controls to examine whether capillary dysfunction can be detected, and whether symptom severity across patients correlates with the degree of capillary dysfunction in certain brain regions. To our knowledge there have been no previous studies on cognitive impairment and its origin in patients with HypoPT. The investigators hypothesize that the symptoms of HypoPT patients represent various degrees of capillary dysfunction, which interfere with their brain function.

Read the detailed description

Hypoparathyroidism (HypoPT) is a disease with inadequate production of parathyroid hormone (PTH) from the parathyroid glands leading to hypocalcemia. The most common form is postsurgical HypoPT due to neck surgery resulting in removed or damaged parathyroid glands. Postsurgical HypoPT has a prevalence of 22/100,000 inhabitants in Denmark. Nonsurgical HypoPT is most often caused by mutations in different genes or on an autoimmune basis, the prevalence of nonsurgical HypoPT is 2.3/100,000 inhabitants in Denmark. If the gene mutation is within the GNAS gene or upstream of the GNAS complex locus it causes PseudoHypoPT (PHP), which is characterized by target organ resistance to PTH, also resulting in hypocalcaemia and hyperphosphatemia as in post- and nonsurgical HypoPT, but in this case with high or normal levels of plasma PTH. PHP is a very rare disease with a prevalence of 1/100,000 inhabitants in Denmark.

Others and the investigators have previously shown that HypoPT and/or hypocalcemia may affect quality of life (QoL). In most cases, severe symptoms and findings diminished or disappeared when plasma calcium levels are restored to normal, but as some of the above mentioned studies have shown, the reduced QoL is still present despite normal calcium levels. Symptoms are describes as minor cognitive impairment (MCI), with confusion, forgetfulness, and lack of focus and mental clarity. Another important finding in some of the patients with HypoPT is calcifications of the basal ganglia as described in several case reports, the knowledge of the origin and importance of these is so far limited. Patients with PHP have previously been described to have a higher risk of calcifications of the lens and subcutaneous calcifications, and therefore might also be at higher risk of calcifications in the brain.

The oxygen availability in brain tissue is traditionally thought to depend on regional cerebral blood flow (CBF). Accordingly, brain oxygenation is only expected to impair brain function in cases where CBF is critically reduced, cerebral ischemia. This paradigm was recently shown to be in error: While CBF determines the oxygen supply, the microscopic distribution of blood flows across the capillary bed determines the extent to which this oxygen can be extracted by the tissue. In fact, capillary flow patterns can become so disturbed that the metabolic needs of brain function and survival can no longer be met - although CBF remains inconspicuous. Capillary dysfunction denotes this overlooked source of hypoxia: A state in which capillary flow patterns cannot homogenize, giving rise to tissue hypoxia, oxidative stress, local inflammation, and - if severe - long-term neurodegeneration. The investigators hypothesize that the symptoms of HypoPT patients represent various degrees of capillary dysfunction, which interfere with their brain function.

The purpose of the study is to investigate whether HypoPT patients are affected by capillary dysfunction, a condition in which capillary flow disturbances interfere with brain oxygenation.

The hypothesis derives from findings that cerebral calcifications similar to those found in HypoPT are observed in familial idiopathic basal ganglia calcification (IBGC), which is a disease of cerebral pericytes. Pericytes are localized in the basement membrane of capillaries, where they maintain blood brain barrier (BBB) function and - in close interaction with endothelial cells - basement membrane and capillary wall integrity. They are contractile and take part in blood flow regulation. They control the trafficking of immune cells across the vessel wall and possess stem/progenitor cell functions. As such, they play a key role in tissue repair, scarring, and fibrosis, and along with endothelial cells, they seemingly have the potential to become bone-forming cells.

Pericytes (now referred to as 'mural cells') are characterized by several membrane proteins, one of which (SLC9A3R1 - solute carrier family 9, isoform A3, regulatory factor 1, also known as EBP50, NHERF) binds to parathyroid hormone 1 receptor (PTH1R) on one hand, and to plasma derived growth factor (PDGF) receptor β (PDGFβ) on the other, potentiating its activity. The physiological role of these receptors is poorly understood. Receptors for PTH and Parathyroid hormone-related protein (PTH-rP) have been observed in both pericytes and smooth muscle cells of various tissue types, while PTH-rP is expressed in the endothelium, acting as a vasodilator. There is hence reason to believe that the function of capillary pericytes - and hence capillary flow patterns - could be altered in HypoPT.

The investigators have developed a contrast-enhanced, magnetic resonance imaging (MRI) based method to detect disturbances in microvascular flow patterns in the human brain and demonstrated that knowledge of these flow patterns - as indexed by the capillary transit-time heterogeneity (CTH) - allow us to better predict oxygen extraction efficacy as determined by a gold-standard positron emission tomography (PET). The investigators have now found abnormal microvascular flow patterns in patients with Alzheimer's disease (AD) or mild cognitive impairment (MCI) compared to healthy, age-matched controls without cardiovascular risk factors, and demonstrated that the degree of capillary dysfunction correlated with their cognitive impairment. The investigators found a similar correlation in another AD patient cohort, and most recently detected capillary dysfunction in patients with late-onset depression compared to controls. In view of these findings, and the similarity between the symptomatology of HypoPT and depression, the investigators now propose to apply our MRI method to HypoPT patients and age- and gender matched controls to examine whether capillary dysfunction can be detected, and whether symptom severity across patients correlates with the degree of capillary dysfunction in certain brain regions.

The aim is to investigate the cognitive function in patients with postsurgical, non-surgical and pseudoHypoPT by neuropsychological assessments and MRI. The contrast-enhanced MRI based method will be applied to HypoPT patients and age- and gender matched controls to examine whether capillary dysfunction can be detected, and whether symptom severity across patients correlates with the degree of capillary dysfunction in certain brain regions.

The investigators hypothesize that the symptoms of HypoPT patients represent various degrees of capillary dysfunction, which interfere with their brain function.

Methods:

MRI scans: The investigators plan to acquire the following MRI sequences:

  1. Dynamic susceptibility contrast perfusion MRI will be applied for measurement of capillary function and regional blood flow and volume as estimated by our by parametric approach.
  2. For further characterization of the microcirculation, resting state functional MRI will be acquired. This sequence can be acquired in combination with the perfusion scan and thus requires very little extra scanning time.
  3. Fluid attenuated inversion recovery (FLAIR) images will be acquired for estimation of white matter hyperintensities (WMH) and possible subcortical infarcts or lacunas.
  4. A fast diffusion kurtosis imaging (DKI) sequence will be applied for estimation of microstructural integrity of gray and white matter (e.g. dendrite density and white matter tract integrity).
  5. T1-weighted MRI will be utilized for accurate morphological characterization of cerebral structures, such as hippocampus, basal ganglia, cortex and major tracts. In addition, the high-resolution images enable accurate mapping of the functional data (perfusion, fMRI, DKI).

Neuropsychological testing (NPT): The standard neuropsychological test battery consists of validated tests to assess cognitive domains including verbal and visual memory, attention, language, visuospatial and executive functioning.

Cognitive batteries: Cogstate battery for assessing cognitive function in adults with mild cognitive impairment (MCI). The tests used are D-KEFS: TrailMaking A and B, Verbal Fluency Test, and Color-Word Interference Test. The WAIS-IV: Coding, Symbol search, Digit span, and Arithmetic. The BVMT-R: delayed recall and total learning. Lastly the RAVLT: delayed recall and total learning.

Questionnaires: SF36v2, WHO-5 well-being index, Symptom questionnaire, and a general questionnaire on background information, medication and diet, and HPQ28.

Biochemistry: Ionized calcium, PTH, phosphate, magnesium, eGFR, creatinine, High sensitive CRP, 25-hydroxyvitamin D, calcitriol, and white blood cell count. Neuroinflammation and systemic inflammatory markers (pro-inflammatory cytokines), and 24-hr urine.

Statistical Analysis Plan: Group difference will be examined using student T test for continuous variables and Pearsons X^2 test for categorical variables. Statistical maps of differences in perfusion parameters between patients and controls will be calculated at each surface vertex using a vertex specific general linear model with cortical thickness, white matter hyperintensity load ((WMHL) given as percentage white matter hyperintensities volume of whole brain volume)), age, and gender as covariates. The investigators will add cortical thickness as covariate to account for any systematic effects of cortical thickness on the perfusion measurements, such as partial volume effects. All statistical maps will be thresholded at p=0.05 (uncorrected and corrected). All statistical tests for the MRI scans are carried out using R version 3.2.2 (The R Foundation for Statistical Computing) and SPM12 (Wellcome Trust Centre for Neuroimaging) running on Matlab R2016a (MathWorks Inc). Other statistical test will be carried out by SPSS 24 (IBM, USA) Justification for sample size: In a previous study by Eskildsen et al. the contrast-enhanced MRI based method has been applied to 18 patients with Alzheimer's disease or MCI compared to 19 healthy, age-matched controls without cardiovascular risk factors and it demonstrated that the degree of capillary dysfunction correlated with their cognitive impairment. The investigators found a similar correlation in another patient cohort with Alzheimer's disease, and most recently detected capillary dysfunction in patients with late-onset depression compared to controls. Taking the above mentioned results and the sizes of the cohorts in consideration, the investigators have estimated that our sample size is enough to show if there is a correlation between cognitive impairment measured by neuropsychological assessment and capillary transit time heterogeneity.

Safety and ethnical evaluations: The investigators will follow the standard operating procedures regarding contrast enhanced MRI scans. Peripheral venous catheter will be used for administration of PET tracers and MRI contrast. It can result in mild local pain and a hematoma. The risk of infection is negligible. There are no known risks (neither short- nor long-term) related to MRI. Gadolinium-chelate (Gd) contrast is used. The standard dose of gadolinium (Gd)-containing MRI-contrast is 0.1 mmol/kg, but in this study there will be used up to 0.3 mmol/kg.

Perspectives: If successful and study findings provides a basis for improved understanding of cognitive symptoms in HypoPT, further investigations on effects of PTH replacement therapy on investigated indices should be considered. A future project could be performing the MRI scan before and after injection of PTH to determine whether a change in capillary transit time heterogeneity could be detected.

Being tested
MRI scans, Neuro cognitive tests, Questionnaires on Quality of Life, Blood samples, 24 hr urine samples
Keywords
Quality of Life, MRI, Cognitive Impairment, Hypoparathyroidism, Pseudohypoparathyroidism
Medical subject headings
Hypoparathyroidism, Pseudohypoparathyroidism, Cognitive Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MRI scansDiagnostic test

    Contrast-enhanced, magnetic resonance imaging (MRI) based method to detect disturbances in microvascular flow patterns in the human brain

  • Neuro cognitive testsDiagnostic test

    Standard neuropsychological test battery consists of validated tests to assess cognitive domains including verbal and visual memory, attention, language, visuospatial and executive functioning.

  • Questionnaires on Quality of LifeDiagnostic test

    SF36v2, WHO-5 well-being index, HPQ28, Symptom questionnaire, and a general questionnaire on background information, medication and diet.

  • Blood samplesDiagnostic test

    Markers of calcium homeostasis, inflammatory markers and hematology.

  • 24 hr urine samplesDiagnostic test

    24 hr urine content of calcium, phosphate, magnesium, and creatinine.

Study groups in NCT04569604
Study groupRoleWhat they receive
Postsurgical hypoparathyroidismPatients with hypoparathyroidism for 3 or more years after neck surgery
Receives: Diagnostic Test: MRI scans; Diagnostic Test: Neuro cognitive tests; Diagnostic Test: Questionnaires on Quality of Life; Diagnostic Test: Blood samples; Diagnostic Test: 24 hr urine samples
Non-surgical hypoparathyroidismPatients with hypoparathyroidism for 3 or more years without neck surgery
Receives: Diagnostic Test: MRI scans; Diagnostic Test: Neuro cognitive tests; Diagnostic Test: Questionnaires on Quality of Life; Diagnostic Test: Blood samples; Diagnostic Test: 24 hr urine samples
PseudohypoparathyroidismPatients with the diagnosis of Pseudohypoparathyroidism
Receives: Diagnostic Test: MRI scans; Diagnostic Test: Neuro cognitive tests; Diagnostic Test: Questionnaires on Quality of Life; Diagnostic Test: Blood samples; Diagnostic Test: 24 hr urine samples
Healthy controls25 controls from the background population matched on age (±3 years), gender and level of education with the 25 patients with postsurgical hypoparathyroidism
Receives: Diagnostic Test: MRI scans; Diagnostic Test: Neuro cognitive tests; Diagnostic Test: Questionnaires on Quality of Life; Diagnostic Test: Blood samples; Diagnostic Test: 24 hr urine samples

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Capillary transit time heterogeneity

    Capillary transit time heterogeneity is measured by MRI scans

    Measured: MRI scan performed at baseline, no follow-up up. It takes 1 hour to perform

Secondary outcomes (8)
  1. Index 1: Processing speed

    Index 1 consist of the following tests

    1. Coding (WAIS-IV) scaled score
    2. Symbol search (WIAS-IV) scaled score

    A composit score from the above tests will be calculated and compared to the control group and normative data.

    Measured: Neuropsychological tests are performed immediately before or immediately after the MRI scan and scheduled to take 1½ hours.

  2. Index 2: Working memory

    Index 2 consist of the following tests

    1. Digit span (WAIS-IV) scaled score
    2. Arithmetic (WAIS-IV) scaled score

    A composit score will be calculated from the above tests and compared to the control group and normative data.

    Measured: Neuropsychological tests are performed immediately before or immediately after the MRI scan and scheduled to take 1½ hours.

  3. Index 3: Executive function

    Index 3 consist of the following tests

    1. Trail Making Test (D-KEFS) scaled score
    2. Verbal Fluency Test (D-KEFS) scaled score
    3. Color-Word Interference Test (D-KEFS) scaled score

    A composit score will be calculated from the above tests and compared to the control group and normative data.

    Measured: Neuropsychological tests are performed immediately before or immediately after the MRI scan and scheduled to take 1½ hours.

  4. Index 4: Verbal learning and memory

    Index 4 consist of the following tests

    1. Rey Auditory Verbal Learning Test (RAVLT) total learning scaled score
    2. Rey Auditory Verbal Learning Test (RAVLT) delayed recall scaled score

    A composit score will be calculated from the above tests and compared to the control group and normative data.

    Measured: Neuropsychological tests are performed immediately before or immediately after the MRI scan and scheduled to take 1½ hours.

  5. Index 5: Visual learning and memory

    Index 4 consist of the following tests

    1. Brief Visuospatial Memory Test-Revised (BVMT-R) total learning scaled score
    2. Brief Visuospatial Memory Test-Revised (BVMT-R) delayed recall scaled score

    A composit score will be calculated from the above tests and compared to the control group and normative data.

    Measured: Neuropsychological tests are performed immediately before or immediately after the MRI scan and scheduled to take 1½ hours.

  6. Correlation of calcifications in the brain and cognitive function.

    Calcifications:

    The calcifications will be visually inspected on the PETRA sequense of the MRI scans.

    It will defined by its location (Globus pallidus, Thalamus, caudate nucleus, cortex, putamen, or cerebellum) and then defined in accordance with its size as listed below:

    The calcifications are going to be divided into 4 categories according to size:

    1. "barely recognizable" / up to approx. 1 mm,
    2. "small" / up to approx. 3 mm,
    3. "medium" / up to approx. 8 mm,
    4. "large" / approx. > 8 mm. The size classification will be based on segmentation of the calcification finding the maximum cross section measured.

    The most severe score will be attributed if more than one calcification is present in one location.

    The calcifikation load of the patient will be an addition of scores from the different locations.

    There will be tested for a correlation of the calcification load and the scores from the Index 1, 2, 3, 4, and 5 of the neuropsychological tests.

    Measured: The MRI scan: Baseline visit (duration 1 hr.). Neuropsychological tests are performed immediately before or immidiatly after the MRI.The analyses of the calcifications: Three months after the last subject has finished the study ( duration 1-2 mo)

  7. Difference in capillary transit time heterogeneity between patients and healthy controls

    Capillary transit time heterogeneity is measured by MRI scans and compared between groups

    Measured: MRI scan performed at baseline, no follow-up up. It takes 1 hour to perform

  8. Difference in Quality of Life between patients and healthy controls.

    Quality of life is measured by three different questionnaires.

    1. 36-Item Short Form Survey version 2 (SF36v2): A questionnaire with 36 questions on mental and physical complaints. The higher score, the better.
    2. : The WHO-5 wellbeing index: 5 questions on well being. The higher score the better.
    3. HPQ-28: A disease specific questionnaire designed for patients with Hypoparathyriodsm. The lower the score the better.

    Measured: The questionnaires were completed online within 3 weeks after the day with the MRI scand and the neurocognitive testing.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Sep 2020
  2. Study start1 Oct 2019
  3. Primary completion1 Oct 2020
  4. Study completion1 Dec 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
64 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04569604
Sponsor's protocol ID
#11102018
Other IDs
1-10-72-304-18
Acronym
MR-hypoPT
Status last verified
Dec 2021
First submitted
2 Sep 2019
Last updated
23 Dec 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013 Nov;28(11):2277-85. doi: 10.1002/jbmr.1979.

    PubMed 23661265
  • Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. The Epidemiology of Nonsurgical Hypoparathyroidism in Denmark: A Nationwide Case Finding Study. J Bone Miner Res. 2015 Sep;30(9):1738-44. doi: 10.1002/jbmr.2501. Epub 2015 May 31.

    PubMed 25753591
  • Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Pseudohypoparathyroidism - epidemiology, mortality and risk of complications. Clin Endocrinol (Oxf). 2016 Jun;84(6):904-11. doi: 10.1111/cen.12948. Epub 2015 Oct 19.

    PubMed 26387561
  • Bohrer T, Krannich JH. Depression as a manifestation of latent chronic hypoparathyroidism. World J Biol Psychiatry. 2007;8(1):56-9. doi: 10.1080/15622970600995146.

    PubMed 17366354
  • Lawlor BA. Hypocalcemia, hypoparathyroidism, and organic anxiety syndrome. J Clin Psychiatry. 1988 Aug;49(8):317-8.

    PubMed 3045102
  • Snowdon JA, Macfie AC, Pearce JB. Hypocalcaemic myopathy with paranoid psychosis. J Neurol Neurosurg Psychiatry. 1976 Jan;39(1):48-52. doi: 10.1136/jnnp.39.1.48.

    PubMed 1255212
  • Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, Allolio B. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002 Feb;146(2):215-22. doi: 10.1530/eje.0.1460215.

    PubMed 11834431
  • Astor MC, Lovas K, Debowska A, Eriksen EF, Evang JA, Fossum C, Fougner KJ, Holte SE, Lima K, Moe RB, Myhre AG, Kemp EH, Nedrebo BG, Svartberg J, Husebye ES. Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway. J Clin Endocrinol Metab. 2016 Aug;101(8):3045-53. doi: 10.1210/jc.2016-1477. Epub 2016 May 17.

    PubMed 27186861
  • Sikjaer T, Moser E, Rolighed L, Underbjerg L, Bislev LS, Mosekilde L, Rejnmark L. Concurrent Hypoparathyroidism Is Associated With Impaired Physical Function and Quality of Life in Hypothyroidism. J Bone Miner Res. 2016 Jul;31(7):1440-8. doi: 10.1002/jbmr.2812. Epub 2016 Mar 31.

    PubMed 26865527
  • Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L. Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int. 2014 Jun;25(6):1717-26. doi: 10.1007/s00198-014-2677-6. Epub 2014 Apr 1.

    PubMed 24687385
  • Velasco PJ, Manshadi M, Breen K, Lippmann S. Psychiatric aspects of parathyroid disease. Psychosomatics. 1999 Nov-Dec;40(6):486-90. doi: 10.1016/s0033-3182(99)71186-2.

    PubMed 10581976
  • Underbjerg L, Sikjaer T, Rejnmark L. Health-related quality of life in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism. Clin Endocrinol (Oxf). 2018 Jun;88(6):838-847. doi: 10.1111/cen.13593. Epub 2018 Apr 3.

    PubMed 29520810
  • Abiusi G, Dominguez RO, Parada Marcilla M, Lesyk S, Laguarde N, Yobstraibizer F. [Asymptomatic encephalic calcifications in postsurgical hypoparathyroidism]. Neurologia. 2009 Sep;24(7):454-6. Spanish.

    PubMed 19921554
  • Basak RC. A case report of Basal Ganglia calcification - a rare finding of hypoparathyroidism. Oman Med J. 2009 Jul;24(3):220-2. doi: 10.5001/omj.2009.44.

    PubMed 22224190
  • Bhimani S, Sarwar M, Virapongse C, Rojas R, Freilich M. Computed tomography of cerebrovascular calcifications in postsurgical hypoparathyroidism. J Comput Assist Tomogr. 1985 Jan-Feb;9(1):121-4. doi: 10.1097/00004728-198501000-00022.

    PubMed 3968258

Questions about this trial

What is this clinical trial studying?

An observational study of Hypoparathyroidism and Pseudo Hypoparathyroidism, run by University of Aarhus at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Capillary transit time heterogeneity (time frame: MRI scan performed at baseline, no follow-up up. It takes 1 hour to perform). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04569604, which also lists 56 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in